Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Lower CD4 T cell reactivity to seasonal coronaviruses found in healthcare workers with COVID-19

A new study by US-based researchers describes the results of a study on the immune response among healthcare workers, in particular, their T cell responses predating the pandemic.

19 Jan 2021

Early administration of ivermectin could help reduce viral transmission in COVID-19 patients

A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission.

19 Jan 2021

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

An interesting new preprint published on the medRxiv server describes an immunosuppressed patient with coronavirus disease 2019 (COVID-19) who continued to shed the virus for an astounding 154 days. During this period, the virus underwent numerous mutations.

19 Jan 2021

Genomics reveals distinct patterns of emergence of SARS‐CoV‐2 spike variants in Columbus, Ohio

Recently researchers from the United States reported the results of a SARS‐CoV‐2 genomic surveillance conducted between April 2020 and January 2021 in Columbus, Ohio. Their work is released as a preprint on the bioRxiv server.

18 Jan 2021

Closed SARS-CoV-2 spikes could be a valuable component of future vaccines

Now, researchers at the Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom, reveal that engineered closed S constructs may be valuable immunogens that can induce neutralizing antibodies against a different pattern of epitopes. This allows for the flexibility of vaccines at both the individual and population levels.

18 Jan 2021

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

What are the key factors and impact of interventions in England’s COVID-19 epidemic?

Researchers from Imperial College London provide a mathematical model to help understand how SARS-CoV-2, the causative pathogen of (COVID-19), spread across England in the first two waves of the epidemic, and the effect of various interventions by the government.

18 Jan 2021

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

An interesting new preprint research paper that was posted on the bioRxiv* server recently describes the use of rigid monoclonal antibodies (mAbs) in contrast to flexible mAbs, and how this affects the binding of multiple mAbs to the same antigen.

17 Jan 2021

Study: Fibroblast hormone promotes movement of hematopoietic stem cells

Discovery expected to contribute towards more effective methods of harvesting stem cells from bone marrow donors.

17 Jan 2021

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

There have been significant efforts worldwide to combat COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One prominent strategy has been to develop vaccines against the virus. Numerous vaccine candidates are under development, and a handful have now been approved for use by several countries.

17 Jan 2021

Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine

Researchers in the Netherlands, the United States, and Belgium have presented early-stage clinical trial results demonstrating the safety and efficacy of Johnson & Johnson's vaccine candidate for coronavirus disease 2019 (COVID-19).

17 Jan 2021

Study reveals possible SARS-CoV-2 escape mutant that may re-infect immune individuals

A recent study by US researchers shows how the 501Y.V2 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterized by several mutations, is able to escape neutralization by present first-wave anti-SARS-CoV-2 antibodies and potentially re-infect COVID-19 convalescent individuals.

17 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Researchers discover antibody that blocks the spread of dengue virus

A team of researchers led by the University of California, Berkeley and the University of Michigan has discovered an antibody that blocks the spread within the body of the dengue virus, a mosquito-borne pathogen that infects between 50 and 100 million people a year.

14 Jan 2021

Drug found to be safe and effective for treating patients with obesity and type 2 diabetes

A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.

13 Jan 2021

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

Researchers at Columbia University have provided important insights into features of viral binding and recognition within a class of potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.

13 Jan 2021

New technology could protect against different coronavirus variants

The SARS-CoV-2 virus that is causing the COVID-19 pandemic is just one of many different viruses in the coronavirus family.

13 Jan 2021

Antibody News and Research

Further Reading

Lower CD4 T cell reactivity to seasonal coronaviruses found in healthcare workers with COVID-19

Early administration of ivermectin could help reduce viral transmission in COVID-19 patients

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

Genomics reveals distinct patterns of emergence of SARS‐CoV‐2 spike variants in Columbus, Ohio

Closed SARS-CoV-2 spikes could be a valuable component of future vaccines

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

What are the key factors and impact of interventions in England’s COVID-19 epidemic?

SARS-CoV-2 anti-N rigid monoclonal antibodies provide accurate early diagnosis

Study: Fibroblast hormone promotes movement of hematopoietic stem cells

A high-temperature tolerant SARS-CoV-2 derived immunogen as a potential vaccine candidate

Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine

Study reveals possible SARS-CoV-2 escape mutant that may re-infect immune individuals

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Researchers discover antibody that blocks the spread of dengue virus

Drug found to be safe and effective for treating patients with obesity and type 2 diabetes

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

New technology could protect against different coronavirus variants

Accelerating therapeutic antibody discovery and development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo